Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with obesity but no diabetes. It also improved multiple cardiometabolic markers with a safety profile similar to other GLP-1 receptor agonists.

Daily obesity pill Orforglipron helped adults lose up to 20% of their body weight in global trial

Obesity is one of the most stubborn health challenges of our time, linked with diabetes, heart disease, sleep problems, and shortened lifespans. Doctors have long sought treatments that not only help with weight loss but are also safe and practical for everyday use. A new study points to an oral medication that could be a game-changer: Orforglipron. What makes this drug stand out is simple—it comes in pill form. While many similar medications mu…